title: Results of high dose intravenous urokinase for acute myocardial infarction.
abstract: To determine the outcome of patients after treatment with high-dose intravenous urokinase (3 million U) 102 patients were prospectively evaluated in the setting of acute myocardial infarction. The first 61 patients received intravenous urokinase as a continuous infusion and the last 41 patients were treated with an initial 1.5 million U intravenous bolus. Sixty-two percent of all patients had patent infarct-related arteries by the time of immediate angiography (median time 2.2 hours), which was performed in all patients. There was no significant difference in patency rates between patients treated with or without an initial intravenous bolus. Twenty-eight (28%) patients developed clinical evidence of recurrent ischemia (death, reocclusion, emergency angioplasty, urgent bypass surgery) during hospitalization, whereas only 7 (7%) developed angiographically documented reocclusion. Of 28 patients who failed to achieve successful reperfusion at the time of immediate catheterization, rescue angioplasty was technically successful in establishing reperfusion in all but 1 patient. No significant improvement in median global left ventricular function was seen between immediate (48%) and follow-up catheterization (48%). Significant bleeding complications were unusual except in 1 patient who experienced an intracranial hemorrhage. Eight (8%) patients died during hospitalization. Therefore, the use of high-dose intravenous urokinase in patients with acute myocardial infarction is associated with a 62% patency rate, a low incidence of reocclusion and bleeding complications and a high technical success rate with rescue angioplasty at the time of immediate catheterization.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
authors.forename: T C
authors.initials: TC
authors.lastname: Wall
authors.forename: H R
authors.initials: HR
authors.lastname: Phillips
authors.forename: R S
authors.initials: RS
authors.lastname: Stack
authors.forename: S
authors.initials: S
authors.lastname: Mantell
authors.forename: L
authors.initials: L
authors.lastname: Aronson
authors.forename: J
authors.initials: J
authors.lastname: Boswick
authors.forename: K
authors.initials: K
authors.lastname: Sigmon
authors.forename: M
authors.initials: M
authors.lastname: DiMeo
authors.forename: D
authors.initials: D
authors.lastname: Chaplin
authors.forename: D
authors.initials: D
authors.lastname: Whitcomb
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D003327:Coronary Disease / Q000150:complications / Q000628:therapy; D005500:Follow-Up Studies; D006321:Heart / Q000503:physiopathology; D006352:Heart Ventricles; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D012008:Recurrence; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D014654:Vascular Patency
chemical_list: D014568:Urokinase-Type Plasminogen Activator